Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Apple Turns 50: From Garage Startup to AI Crossroads 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
REDWOOD CITY, Calif., Sept. 01, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare conferences.
- Management participation in a fireside chat is scheduled at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:30 a.m. ET taking place in Boston, MA.
- Management participation in a fireside chat is scheduled at the Baird 2017 Global Healthcare Conference on Thursday, September 7th at 9:05 a.m. ET taking place in New York, NY.
- A company presentation is scheduled at Cantor Fitzgerald’s 3rd Annual Healthcare Conference on Tuesday, September 26th at 8:35 a.m. ET taking place in New York, NY.
The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT: Patrick O'Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 649-3527
